The amount of blood surgical patients can donate and store before surgery can be increased by the new genetically engineered drug EPO EPO or erythropoietin is a protein the human body makes to stimulate the growth of red blood cells A genetically engineered version of the human protein developed by Amgen Corp of <ENAMEX TYPE="LOCATION">Thousand Oaks Calif</ENAMEX> recently has been marketed by the Ortho Pharmaceuticals division of <ENAMEX TYPE="PERSON">Johnson Johnson A</ENAMEX> competing version of EPO is being developed by <ENAMEX TYPE="ORGANIZATION">Genetics Institute Inc</ENAMEX> in <ENAMEX TYPE="LOCATION">Cambridge Mass</ENAMEX> The drug is being used primarily to treat anemias A new experiment reported in this week s <ENAMEX TYPE="LOCATION">New England Journal</ENAMEX> of Medicine involved giving injections of Amgen s EPO to 23 patients who wanted to store units of their own blood The patients began receiving EPO injections about a month before their scheduled surgery They then began donating blood twice a week receiving an EPO injection each time If tests indicated a low number of red cells blood wasn t taken The EPO treated patients donated an average of 5 4 units of blood each compared with only 4 1 units donated by a similar group of surgical patients who received a placebo injection The volume of red cells donated by the EPO treated patients was 41 higher per donor the research team representing a number of hospitals and blood banks reported